Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with autoantibodies to anti-aquaporin-4 (AQP4-IgG) in approximately two thirds of patients. Interleukin-6 is involved in the pathogenesis of the disorder. Satralizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor. The efficacy of satralizumab added to immunosuppressant treatment in patients with NMOSD is unclear.

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Patti, Francesco;
2019-01-01

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with autoantibodies to anti-aquaporin-4 (AQP4-IgG) in approximately two thirds of patients. Interleukin-6 is involved in the pathogenesis of the disorder. Satralizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor. The efficacy of satralizumab added to immunosuppressant treatment in patients with NMOSD is unclear.
File in questo prodotto:
File Dimensione Formato  
Trial of satralizumab in neuromyelitis.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Dimensione 292.99 kB
Formato Adobe PDF
292.99 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/371879
Citazioni
  • ???jsp.display-item.citation.pmc??? 124
  • Scopus 368
  • ???jsp.display-item.citation.isi??? 310
social impact